New frontiers in osteoarthritis treatment: An expert consensus on evolving role of nutraceuticals

Abstract

Osteoarthritis (OA) is a leading cause of pain and disability worldwide, with its prevalence expected to rise due to aging populations and lifestyle factors. Traditional pharmacological treatments primarily offer symptomatic relief without addressing the underlying causes of cartilage degradation, often accompanied by adverse effects. Nutraceuticals, particularly Undenatured Collagen Type II: UC-II®, sourced from Lonza, Switzerland, Mobilee®, sourced from Bioberica, Spain, and Curcumin from Curcuma longa, have emerged as promising alternatives, demonstrating disease-modifying effects with a strong safety profile. This expert opinion paper, based on sessions with 49 top Indian orthopedics, explores the efficacy and tolerability of these nutraceuticals in OA management. The combination of UC-II®, Mobilee®, and Curcumin has shown significant improvements in pain, mobility, and overall quality of life in OA patients, particularly in early-grade OA. Clinical evidence supports the role of these nutraceuticals in reducing inflammation, enhancing cartilage regeneration, and improving synovial fluid properties. Moreover, their safety and efficacy make them suitable for long-term use across diverse patient populations. The paper highlights the importance of appropriate dosing and the potential for these nutraceuticals to improve patient adherence and satisfaction, offering a viable alternative to conventional therapies. The findings advocate for the integration of evidence-based nutraceuticals into standard OA treatment protocols.